Home/Filings/4/0001493152-25-028303
4//SEC Filing

CZIRR JAMES C 4

Accession 0001493152-25-028303

CIK 0001133416other

Filed

Dec 17, 7:00 PM ET

Accepted

Dec 18, 10:34 AM ET

Size

11.5 KB

Accession

0001493152-25-028303

Insider Transaction Report

Form 4
Period: 2025-11-24
Transactions
  • Other

    Common Stock

    2025-11-2424,0005,645,138 total
  • Sale

    Common Stock

    2025-12-16$6.66/sh30,681$204,3355,614,457 total
Transactions
  • Other

    Common Stock

    2025-11-2424,0005,645,138 total
  • Sale

    Common Stock

    2025-12-16$6.66/sh30,681$204,3355,614,457 total
CZIRR JAMES C
Director10% Owner
Transactions
  • Other

    Common Stock

    2025-11-2424,0005,645,138 total
  • Sale

    Common Stock

    2025-12-16$6.66/sh30,681$204,3355,614,457 total
Footnotes (3)
  • [F1]Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law.
  • [F2]10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
  • [F3]The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Documents

1 file

Issuer

GALECTIN THERAPEUTICS INC

CIK 0001133416

Entity typeother

Related Parties

1
  • filerCIK 0001260641

Filing Metadata

Form type
4
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 10:34 AM ET
Size
11.5 KB